Misplaced Pages

Oxanamide: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 21:12, 1 April 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (no changed fields - added verified revid - updated 'UNII_Ref', 'ChemSpiderID_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEMBL_Ref', 'KEGG_Ref') per Chem/Drugbox validation (← Previous edit Latest revision as of 15:07, 31 January 2023 edit undoEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,777 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper 
(19 intermediate revisions by 17 users not shown)
Line 1: Line 1:
{{Short description|Chemical compound}}
{{Drugbox {{Drugbox
| verifiedrevid = 376111334 | verifiedrevid = 421882229
| IUPAC_name = 2-ethyl-3-propyloxirane-2-carboxamide | IUPAC_name = 2-ethyl-3-propyloxirane-2-carboxamide
| image = Oxanamide.png | image = Oxanamide.png

| CAS_number = 126-93-2
<!--Clinical data-->
| ATC_prefix = none
| ATC_suffix = | tradename =
| pregnancy_category =
| PubChem = 31365
| legal_status =
| C = 8 | H = 15 | N = 1 | O = 2
| routes_of_administration =
| molecular_weight = 157.21 g/mol

| bioavailability =
<!--Pharmacokinetic data-->
| metabolism =
| bioavailability =
| elimination_half-life =
| excretion = | metabolism =
| elimination_half-life =
| pregnancy_category=
| excretion =
| legal_status =

| routes_of_administration =
<!--Identifiers-->
| CAS_number = 126-93-2
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 050271194T
| ATC_prefix = none
| ATC_suffix =
| PubChem = 31365
| ChemSpiderID = 29098

<!--Chemical data-->
| C=8 | H=15 | N=1 | O=2
| smiles = CCCC1C(O1)(CC)C(=O)N
| StdInChI = 1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10)
| StdInChIKey = WBLPIVIXQOFTPQ-UHFFFAOYSA-N

}} }}


'''Oxanamide''' ('''Quiactin''') is an ] and ] which can produce ] and ] effects in sufficiently high doses.<ref>{{cite journal|title=Effects of oxanamide on the central nervous system |journal=Proceedings of the Society for Experimental Biology and Medicine |year=1960 |volume=103 |pages=101–3|pmid=14412594|last1=Kuhn|first1=WL|last2=Ketteler|first2=HJ|last3=Van Maanen|first3=EF}}</ref> An uncontrolled trial on patients treated in a clinical ] practice published in 1959 found that oxanamide was efficacious in the treatment of anxiety resulting from ], ], and various other causes, with minimal sedation or other side effects.<ref>{{cite journal| author=Robert B. Woodhull |title=Oxanamide; adjunctive use of a new tranquilizer in gynecology| journal=California Medicine| year=1959 |volume=90 |issue=4 |pages=275–7 | pmid=13638840| pmc=1577644}}</ref> '''Oxanamide''' ('''Quiactin''') is an ] and ] which can produce ] and ] effects in sufficiently high doses.<ref>{{cite journal | vauthors = Kuhn WL, Ketteler HJ, Van Maanen EF | s2cid = 40927309 | title = Effects of oxanamide on the central nervous system | journal = Proceedings of the Society for Experimental Biology and Medicine | volume = 103 | pages = 101–3 | date = January 1960 | pmid = 14412594 | doi = 10.3181/00379727-103-25425 }}</ref> An uncontrolled trial on patients treated in a clinical ] practice published in 1959 found that oxanamide was efficacious in the treatment of anxiety resulting from ], ], and various other causes, with minimal sedation or other side effects.<ref>{{cite journal | vauthors = Woodhull RB | title = Oxanamide; adjunctive use of a new tranquilizer in gynecology | journal = California Medicine | volume = 90 | issue = 4 | pages = 275–7 | date = April 1959 | pmid = 13638840 | pmc = 1577644 }}</ref>


== References == == References ==
Line 29: Line 45:
] ]
] ]
] ]
] ]




{{musculoskeletal-drug-stub}} {{musculoskeletal-drug-stub}}
{{nervous-system-drug-stub}} {{Anxiolytic-stub}}
{{Sedative-stub}}

Latest revision as of 15:07, 31 January 2023

Chemical compound Pharmaceutical compound
Oxanamide
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • 2-ethyl-3-propyloxirane-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC8H15NO2
Molar mass157.213 g·mol
3D model (JSmol)
SMILES
  • CCCC1C(O1)(CC)C(=O)N
InChI
  • InChI=1S/C8H15NO2/c1-3-5-6-8(4-2,11-6)7(9)10/h6H,3-5H2,1-2H3,(H2,9,10)
  • Key:WBLPIVIXQOFTPQ-UHFFFAOYSA-N
  (verify)

Oxanamide (Quiactin) is an anxiolytic and muscle relaxant which can produce sedative and hypnotic effects in sufficiently high doses. An uncontrolled trial on patients treated in a clinical gynecology practice published in 1959 found that oxanamide was efficacious in the treatment of anxiety resulting from premenstrual syndrome, menopause, and various other causes, with minimal sedation or other side effects.

References

  1. Kuhn WL, Ketteler HJ, Van Maanen EF (January 1960). "Effects of oxanamide on the central nervous system". Proceedings of the Society for Experimental Biology and Medicine. 103: 101–3. doi:10.3181/00379727-103-25425. PMID 14412594. S2CID 40927309.
  2. Woodhull RB (April 1959). "Oxanamide; adjunctive use of a new tranquilizer in gynecology". California Medicine. 90 (4): 275–7. PMC 1577644. PMID 13638840.
Anxiolytics (N05B)
5-HT1ARTooltip 5-HT1A receptor agonists
GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators
Hypnotics
Gabapentinoids
(α2δ VDCC blockers)
Antidepressants
Antipsychotics
Sympatholytics
(Antiadrenergics)
Others
Hypnotics/sedatives (N05C)
GABAA
Alcohols
Barbiturates
Benzodiazepines
Carbamates
Imidazoles
Monoureides
Neuroactive steroids
Nonbenzodiazepines
Phenols
Piperidinediones
Quinazolinones
Others
GABAB
H1
Antihistamines
Antidepressants
Antipsychotics
α2-Adrenergic
5-HT2A
Antidepressants
Antipsychotics
Others
Melatonin
Orexin
α2δ VDCC
Others
Skeletal muscle relaxants (M03)
Peripherally acting
(primarily antinicotinic,
NMJ block)
Non-depolarizing
Curare alkaloids
4° ammonium agents
Depolarizing
ACh release inhibitors
Centrally acting
Carbamic acid esters
Benzodiazepines
Nonbenzodiazepines
Thienodiazepines
Quinazolines
Anticholinergics
(Antimuscarinics)
Other
Directly acting


Stub icon

This drug article relating to the musculoskeletal system is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This article about an anxiolytic is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This sedative-related article is a stub. You can help Misplaced Pages by expanding it.

Categories: